Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?

被引:15
|
作者
Abas, Abdul Hawil [1 ]
Marfuah, Siti [1 ]
Idroes, Rinaldi [2 ]
Kusumawaty, Diah [3 ]
Fatimawali [4 ]
Park, Moon Nyeo [5 ]
Siyadatpanah, Abolghasem [6 ]
Alhumaydhi, Fahad A. [7 ]
Mahmud, Shafi [8 ]
Tallei, Trina Ekawati [1 ]
Bin Emran, Talha [9 ]
Kim, Bonglee [5 ]
机构
[1] Sam Ratulangi Univ, Fac Math & Nat Sci, Dept Biol, Manado 95115, North Sulawesi, Indonesia
[2] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Pharm, Banda Aceh 23111, Aceh, Indonesia
[3] Univ Pendidikan Indonesia, Fac Math & Nat Sci Educ, Dept Biol, Bandung 40154, West Java, Indonesia
[4] Sam Ratulangi Univ, Fac Math & Nat Sci, Pharm Study Program, Manado 95115, North Sulawesi, Indonesia
[5] Kyung Hee Univ, Coll Korean Med, Seoul 05253, South Korea
[6] Birjand Univ Med Sci, Ferdows Sch Paramed & Hlth, Birjand 9717853577, Iran
[7] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 52571, Saudi Arabia
[8] Australian Natl Univ, John Curtin Sch Med Res, Dept Genome Sci, Canberra, ACT 0200, Australia
[9] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh
来源
MOLECULES | 2022年 / 27卷 / 07期
基金
新加坡国家研究基金会;
关键词
COVID-19; SARS-CoV-2; Omicron; natural immunity; hybrid immunity; MAIN PROTEASE; TRANSMISSION; MECHANISMS; INFECTION; VACCINES; FUTURE; ORIGIN;
D O I
10.3390/molecules27072221
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing, with no signs of abatement in sight. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of this pandemic and has claimed over 5 million lives, is still mutating, resulting in numerous variants. One of the newest variants is Omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated. As a result, many believe that Omicron provides a natural vaccination, which is the first step toward ending the COVID-19 pandemic. Based on published research and scientific evidence, we review and discuss how the end of this pandemic is predicted to occur as a result of Omicron variants being surpassed in the community. In light of the findings of our research, we believe that it is most likely true that the Omicron variant is a natural way of vaccinating the masses and slowing the spread of this deadly pandemic. While the mutation that causes the Omicron variant is encouraging, subsequent mutations do not guarantee that the disease it causes will be less severe. As the virus continues to evolve, humans must constantly adapt by increasing their immunity through vaccination.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Would New SARS-CoV-2 Variants Change the War against COVID-19?
    Redwan, Elrashdy M.
    Elrashdy, Fatma
    Aljabali, Alaa A. A.
    Baetas-da-Cruz, Wagner
    Barh, Debmalya
    Brufsky, Adam M.
    Hassan, Sk. Sarif
    Lundstrom, Kenneth
    Serrano-Aroca, Angel
    Takayama, Kazuo
    Tambuwala, Murtaza M.
    Uhal, Bruce D.
    Uversky, Vladimir N.
    EPIDEMIOLOGIA, 2022, 3 (02): : 229 - 237
  • [42] Omicron: A highly transmissible SARS-CoV-2 variant
    Rahimi, Farid
    Abadi, Amin Talebi Bezmin
    GENE REPORTS, 2022, 27
  • [43] Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai
    Yang, Dawei
    Weng, Huifen
    Wang, Rui
    Li, You
    Zhang, Hao
    Shao, Shifeng
    Huang, Hunan
    Song, Yuanlin
    Chen, Xiaoyan
    Hou, Dongni
    Wu, Yin
    Lu, Xingwei
    Yang, Wei
    Chen, Zhengguo
    Hu, Xiaohan
    Xuan, Jianwei
    Bai, Chunxue
    Wang, Yaoli
    FRONTIERS IN MEDICINE, 2023, 10
  • [44] Airborne Transmission of the SARS-CoV-2 Delta Variant and the SARS-CoV-2 Omicron Variant
    Lee, Byung Uk
    AEROSOL AND AIR QUALITY RESEARCH, 2022, 22 (01)
  • [45] Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
    Li, Juan
    Song, Rui
    Yuan, Zheng
    Xu, Zheng
    Suo, Luodan
    Wang, Qing
    Li, Yuan
    Gao, Yanlin
    Li, Xiaomei
    Chen, Xiaoyou
    Wu, Jiang
    VACCINES, 2022, 10 (08)
  • [46] Recent insights into SARS-CoV-2 omicron variant
    da Silva, Severino Jefferson Ribeiro
    Kohl, Alain
    Pena, Lindomar
    Pardee, Keith
    REVIEWS IN MEDICAL VIROLOGY, 2023, 33 (01)
  • [47] Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection
    Kim, Jinsoo
    Seo, Hyeonji
    Kim, Han-Wool
    Kim, Dongbum
    Kwon, Hyung-Joo
    Kim, Yong-Kyun
    VIRUSES-BASEL, 2022, 14 (11):
  • [48] From the original SARS-CoV-2 strain to the Omicron variant: Predictors of COVID-19 in ambulatory symptomatic children
    Cohen, R.
    Rybak, A.
    Ouldali, N.
    Angoulvant, F.
    Bechet, S.
    Gajdos, V
    Hau, I.
    Sellam, A.
    Ghomari, I. El Aouane El
    Elmerich, F.
    Batard, C.
    Auvrignon, A.
    Grimprel, E.
    Favier, M.
    Jung, C.
    Levy, C.
    INFECTIOUS DISEASES NOW, 2022, 52 (08): : 432 - 440
  • [49] Properties of the Omicron Variant of SARS-CoV-2 Affect Public Health Measure Effectiveness in the COVID-19 Epidemic
    Furuse, Yuki
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (09)
  • [50] Headache as a COVID-19 onset symptom or Post-COVID symptom according to the SARS-CoV-2 Variant
    Fernandez-de-Las-Penas, Cesar
    Cuadrado, Maria L.
    Gomez-Mayordomo, Victor
    Garcia-Azorin, David
    Arendt-Nielsen, Lars
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (02) : 179 - 186